Skip to Main

Jens Grueger is Boston Consulting Group's senior expert for pricing and market access in health care, and a core member of the firm's Health Care practice. He is currently a BCG Henderson Institute (BHI) fellow, exploring a system-of-systems approach to solving global crises, with a focus on health equity. Jens was a founding member, and is now co-chair, of the BCG Market Access Roundtable, that brings together senior access leaders from 28 pharmaceutical companies.

He is also an Affiliate Professor of Health Economics at the Comparative Health Outcomes, Economics and Policy (CHOICE) Institute at the University of Washington in Seattle, and was the 2020-2021 President of ISPOR, the largest professional society for health economics and outcomes research.

Jens joined BCG in 2019 after 25 years in the pharmaceutical industry, where he led the Global Pricing, Market Access, and Health Policy functions at Novartis, Pfizer, and Roche.

AREAS OF EXPERTISE

EDUCATION

  • PhD, theoretical statistics, Technical University of Dortmund
  • Master's, medical statistics, Technical University of Dortmund
  • Vordiplom, Technical University of Dortmund

Publications and Videos

" "

Making Medtech More Equitable

By developing products for a broader base of patients and markets, medtech companies can improve health outcomes, generate business advantages, and contribute to healthier societies overall.
Integrating Health Equity Across a Biopharma Organization | Rectangle

Embedding Health Equity into the Heart of Biopharma

The biopharma industry faces demands for more action to address health inequities. We provide a guide and tools to help companies integrate equity across the product lifecycle.
" "

The Future of Integrated Evidence Planning in Biopharma

Biopharma companies can promote the success of product launches by initiating cross-functional collaboration on evidence generation early in the development process.
Nurse sitting at desk typing on keyboard

How Pharma Can Navigate the Shifting Sands of Oncology Treatments

With advances in knowledge, understanding, technology, and data come fragmentation and complexity. Since the bets are big, companies need to evaluate prospects and make their investments count.